Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Role of Synthetic Lethality in ARID1A -Deficient Malignancies

7 Nov 2023

Abstract excerpt

ABSTRACT AT-rich interaction domain 1A (ARID1A), a mammalian switch/sucrose nonfermenting complex subunit, modulates several cellular processes by regulating chromatin accessibility. It is encoded by ARID1A, an immunosuppressive gene frequently disrupted in a many tumors, affecting the proliferation, migration, and invasion of cancer cells. Targeting molecular pathways and epigenetic regulation associated with...

Topics

Join the communities discussing this publication.

Cancer Mechanisms and Therapy
Chromatin Remodeling and Cancer
Peptidase Inhibition and Analysis

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38327752
DOI: 10.36401/jipo-22-37

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Role of Synthetic Lethality in ARID1A -Deficient MalignanciesPMID 38327752Read ↗

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage responseSemantic proximity Read ↗

ARID1A and Its Impact Across the Hallmarks of CancerSemantic proximity Read ↗

Potential therapeutic targets in ARID1A-mutated cancers.Semantic proximity Read ↗

Remodeling of the ARID1A tumor suppressor.Semantic proximity Read ↗

ARID1A in cancer: Friend or foe?Semantic proximity Read ↗

The Role of the AT-Rich Interaction Domain 1A Gene (ARID1A) in Human Carcinogenesis.Semantic proximity Read ↗

ARID1A mutations in cancer development: mechanism and therapy.Semantic proximity Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?Semantic proximity Read ↗

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1ASemantic proximity Read ↗

Recent advances in the ARID family: focusing on roles in human cancerSemantic proximity Read ↗

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.